Jinwon Life Sciences announced on the 19th that its subsidiary VGXI, a leading supplier of plasmid DNA manufacturing and development services, will participate in the Regenerative Medicine Alliance Annual Meeting held in Phoenix, Arizona, USA, from October 7 to 9.
A representative from Jinwon Life Sciences explained, "The Regenerative Medicine Alliance Annual Meeting is a prestigious event known for high-level lectures and networking opportunities attended by companies and investors worldwide. At this meeting, VGXI will showcase its plasmid DNA manufacturing roadmap and highlight its excellent production capabilities and differentiated high-quality manufacturing services."
Park Young-geun, CEO of Jinwon Life Sciences, stated, "VGXI has contributed to the advancement of gene therapy, DNA vaccines, and cell-based therapies through plasmid DNA manufacturing, establishing itself as a trusted partner in the regenerative medicine community based on the quality and excellence of its plasmid DNA. By participating in this meeting, we will emphasize our continuous investment in capacity expansion and process optimization to meet the growing industry demand, engage with industry experts, and seek new opportunities for VGXI's growth and partnerships."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
